{
    "nct_id": "NCT06109272",
    "official_title": "A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment",
    "inclusion_criteria": "* Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology or cytology or clinically by American Association for the Study of Liver Diseases criteria for participants with cirrhosis.\n* Barcelona Clinic Liver Cancer (BCLC) Stage B or C.\n* Child-Pugh A or B7 classification (i.e., total Child-Pugh score of 5, 6, or 7).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior systemic therapy for HCC.\n* Symptomatic, untreated, or actively progressing CNS metastases.\n* History of malignancy other than HCC.",
    "miscellaneous_criteria": ""
}